Protalix BioTherapeutics (PLX) Misses Q1 EPS by 8c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.69 -0.37%
Revenue Growth %: -33.6%
Financial Fact:
GROSS PROFIT (LOSS): 422K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -33.6%
Financial Fact:
GROSS PROFIT (LOSS): 422K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.05), $0.08 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $10.11 million versus the consensus estimate of $21.6 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Empire Petroleum (EP) files $150M mixed shelf
- Anthropic delays planned IPO from October to November - WSJ
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
